Rating: Neutral ｜ Target Price Range: 48–60 RMB ｜ Current Price: 75.51 RMB (2026-07-24 Close)
Margin of Safety: −36% ｜ Time Horizon: 12 Months ｜ Market Cap: 16.9 Billion RMB
| Dimension | Previous (2026-07-24) | Current | Reason for Change |
|---|---|---|---|
| Stance | Neutral | Neutral | Maintained, as valuation premium, though narrowed, remains elevated |
| Confidence | 0.55 | 0.58 | Slightly increased; this round's red team attack/defense is more thorough, scenario anchoring more rigorous |
| Target Price Range | 55–65 RMB | 48–60 RMB | Revised downward; recalibrated consensus estimate scope (2028E non-recurring ex vs. attributable) and exit PE anchoring logic |
| Valuation Assessment | Overvalued | Overvalued | Maintained |
China Scientific Instruments is the only domestic dry vacuum pump company in China to achieve volume application in advanced semiconductor manufacturing processes. Benefiting from the structural demand inflection point of semiconductor equipment localization, the 3–5 year growth thesis is clear. However, the current share price of 75.51 RMB is fully priced—the current price implies that 2028E non-recurring ex net profit must reach 3.3–4.2 billion RMB, which is approximately 3%–30% above the sell-side consensus estimate of about 3.22 billion RMB for 2028E attributable net profit (non-recurring ex lower), while core business non-recurring ex profit is only about 1 billion RMB and gross margin has declined for three consecutive years (from the prospectus: 33.02% → 29.44% → 26.78%). The probability-weighted fair value from the three scenarios is approximately 50 RMB, giving a margin of safety of −36%. We recommend waiting for a pullback to the 50–55 RMB range before reassessing entry.
Key Evidence:
It should be noted that the claim of "only" comes from the company's prospectus. Domestic peers such as Hanbell Precise Machinery and Tungchong Hongrui also have a presence in semiconductor vacuum pumps. However, as of this research, no public evidence of volume supply in advanced nodes below 14nm has been found for these peers. The timeline for the remaining 14 process qualifications is tight—the IR record shows that as of June 2026, some projects had not yet entered testing, so completion by Q4 is uncertain. Full process coverage is a core catalyst but also the largest single downside risk.
Key Evidence:
There is a concern about slowing revenue growth: FY2024 grew 27.1% → FY2025 slowed to 19.3%. The capacity ramp from 10,000 to 26,500 units is a core assumption for the CAGR forecast—the company has never experienced such a large capacity expansion historically, so execution risk cannot be ignored. Although the AI-driven thesis is directionally correct, the quantitative elasticity coefficient for pump quantity per advanced process node lacks independent third-party verification.
Key Evidence:
In 2026Q1, non-recurring ex profit was 27 million RMB (annualized ~108 million RMB), roughly flat compared to FY2025's 103 million RMB—core business profit has not yet shown an accelerating trend. Valuing the stock based on attributable net profit (PE(TTM) only 16.9x) is seriously misleading: non-recurring ex PE is as high as 164x.
Key Evidence:
The decline may partly be structural—the share of low-margin dry vacuum pump revenue increased from ~65% to higher levels. Even if each product's gross margin remains unchanged, the blended gross margin would be dragged down. The Q1 rebound to 31.79% is a positive sign, but a single quarter is insufficient to confirm a trend reversal; verification must await 2026H1 (disclosed in August).
Key Evidence:
PE(TTM) of 16.9x and PB of 6.4x are severely distorted by large financial assets and are not meaningful. The base case exit PE is set at 35–40x, anchored to Atlas Copco's vacuum division mature-stage PE of ~25x plus a domestic substitution growth premium—lower than NAURA (~70x) and AMEC (~75x), given that China Scientific Instruments is listed on the Beijing Stock Exchange with liquidity and company size discounts.
Key Evidence:
It is important to distinguish two concepts of "qualification": For brand-new products starting from zero, customer qualification indeed takes 2–3 years. However, for process steps that have already passed qualification, the time from qualification completion to first volume delivery may be much shorter (the company's IR indicates "ready for delivery after qualification"). Although catalysts are dense, 2026Q1 operating cash flow was still −53.57 million RMB, so the core business's cash generation capacity needs to be tested.
| Item | FY2023 | FY2024 | FY2025 | 2026Q1 |
|---|---|---|---|---|
| Revenue (100 million RMB) | 8.52 | 10.82 | 12.91 | 2.56 |
| Revenue YoY | — | +27.1% | +19.3% | +38.9% |
| Attributable Net Profit (100 million RMB) | 6.00 | 1.93 | 8.44 | 1.72 |
| Non-recurring Ex Attributable Net Profit (100 million RMB) | 0.73 | 0.88 | 1.03 | 0.27 |
| Comprehensive Gross Margin | 33.02% (Prospectus) | 29.44% (Prospectus) | 26.78% (Prospectus) | 31.79% (Calculated in this report) |
| Net Margin (Attributable) | 70.5% | 17.8% | 65.4% | 67.0% |
| Operating Cash Flow (100 million RMB) | 0.47 | 1.77 | 1.92 | −0.54 |
| Free Cash Flow (100 million RMB) | — | — | 1.02 | — |
| Cash + Cash Equivalents (100 million RMB) | — | — | 22.52 | 23.42 |
| Interest-bearing Debt (100 million RMB) | — | — | 2.42 | 2.27 |
| Debt/Asset Ratio (Consolidated) | — | — | 34.17% (Q1 report) | 32.13% (Q1 report) |
| Net Debt/EBITDA | — | — | Net Cash | Net Cash |
Reasons for Changes in Indicators (≥ ±20% YoY):
In 2026Q1, the company achieved revenue of 256 million RMB (+38.9% YoY), exceeding the upper end of the company's own forecast disclosed in the prospectus (230–250 million RMB). Non-recurring ex net profit was 27 million RMB (vs. −2.12 million RMB in the prior-year period), turning positive from core operations. Comprehensive gross margin was 31.79%, up 5.01 pp from FY2025's full-year 26.78%—partly due to Q1 product mix fluctuations; confirmation of a trend inflection requires 2026H1 data.
However, attributable net profit of 172 million RMB included 166 million RMB from fair value changes of Toptech shares (Toptech's stock price rose from 174 RMB to 423 RMB in Q1, a gain of 143%). Core business contribution was only about 6 million RMB. Operating cash flow was −54 million RMB (improved 53% YoY); Q1 is traditionally a weak season for cash collection, with full-year collection concentrated in H2.
Contract liabilities were 232 million RMB (+82.5% YoY), indicating a strong order backlog. The company did not release quarterly guidance, but the sell-side consensus for FY2026 expects revenue of approximately 1.6 billion RMB and non-recurring ex profit of about 130 million RMB. Q1 completed 16.0% and 20.8% of those figures, respectively, roughly in line with seasonal patterns.
Business Model Description: China Scientific Instruments is a semiconductor equipment component manufacturer with high asset intensity and high technological barriers. Its core product, dry vacuum pumps, is a consumable key component in wafer fabrication, featuring a "razor + blade" model—equipment sales (dry pumps) are one-time revenue, while subsequent maintenance and service provide recurring revenue. The company is backed by the Chinese Academy of Sciences system and owns three national-level R&D platforms and 103 invention patents. Revenue breakdown: approximately 65% from IC, 18% from scientific research vacuum equipment, 11% from maintenance services, and 6% from spare parts. Downstream customers include leading semiconductor companies such as YMTC, CXMT, SMIC, NAURA, and Toptech.
Cash Content of Earnings:
OCF/non-recurring ex was maintained at 1.86–2.02x in FY2024–FY2025, indicating good cash conversion from core earnings. However, FY2023 was only 0.65x, reflecting historical issues of slow collections from downstream photovoltaic customers. Note that 2026Q1 OCF was still −54 million RMB (seasonal); whether full-year positive cash flow can be sustained remains to be seen.
Recurring Earnings Check: FY2025 non-recurring ex profit of 103 million RMB versus attributable net profit of 844 million RMB shows a massive difference—741 million RMB came from non-recurring items (mainly Toptech FV changes). Government subsidies of 130 million RMB exceeded non-recurring ex profit of 103 million RMB—strictly speaking, "pure operating profit" after excluding government subsidies is negative (about −27 million RMB). However, some government subsidies are related to daily operations (e.g., R&D subsidies) and under A-share accounting standards, can be classified as recurring items—there is a gray area in the classification.
Return on Capital: ROIC ≈ 4.2% (non-recurring ex NOPAT of 103 million RMB / (interest-bearing debt 242 million RMB + equity 2,474 million RMB)). Far below the 15% moat threshold and estimated WACC (9–10%), reflecting low core business returns. However, the company is on the cusp of significant capacity expansion (10,000 → 26,500 units), so ROIC being depressed during the investment phase is a temporary characteristic.
Maintenance CapEx Scrutiny: FY2025 CapEx 90 million RMB / Depreciation about 36 million RMB = 2.47x. CapEx/Depreciation > 1.5 indicates a high capital investment phase—consistent with the company's large-scale expansion, not a "capital black hole" (expansionary, not maintenance).
Moat/Red Flags:
Word-Deed Consistency: Management's forecast for 2026Q1 (disclosed in the prospectus) was conservative—expected revenue 230–250 million RMB and non-recurring ex profit 19–23 million RMB. Actual figures were 256 million RMB and 27 million RMB, both exceeding the upper end. Management style is pragmatic. However, there were three oral warnings from the NEEQ system (accounting error correction, violation of fundraising usage, failure to timely deliberate related-party transactions). Governance details have issues but have been rectified. Overall assessment: Pragmatic, occasional governance flaws.
Shareholder Friendliness: The company has paid dividends for four consecutive years during the reporting period (cumulative ~241 million RMB from 2022–2025), but the payout ratio fluctuated widely (17%–535%, due to attributable profit including FV fluctuations). No share buyback record. IPO diluted 23.23%. Equity incentives (Shenyang Zhixin/Huiyuan) have tied in the core team; the incentive expenses were fully amortized by March 2025. A new partnership share adjustment generated a small incremental expense of 1.93 million RMB (amortized 2025–2028), a negligible amount. Overall assessment: Neutral.
Risk Signals:
| Segment | Revenue Share (FY2025) | YoY | Business Logic |
|---|---|---|---|
| Dry Vacuum Pumps | 64.70% | +6.58% | Semiconductor components, high barriers for major customer onboarding, asset-intensive manufacturing |
| Scientific Vacuum Instruments | 18.46% | +35.78% | Customized non-standard products for research, large science facilities + thin-film deposition equipment, relatively high margin |
| Maintenance & Repair Services | 10.61% | +74.45% | Recurring service revenue, grows with installed base |
| Spare Parts & Others | 6.23% | +81.80% | Accessory sales, positively correlated with equipment installed base |
Profit Mainstay Segment: Dry vacuum pumps have the highest revenue share (64.70%) but the lowest gross margin (FY2025 only ~24.23%, per broker estimates), with a three-year downtrend. Scientific vacuum instruments have significantly higher gross margin (estimated 35–45%) but limited revenue scale (18.46% share). Maintenance services have the highest gross margin (estimated 40–50%) and grow with the cumulative installed base of over 40,000 units—this is the key variable for future profit structure optimization.
Gross Margin Structure Differences: Dry vacuum pump gross margin (~24%) vs. maintenance services (~45%+) shows a gap of over 20 pp—the former is a competitive hardware sale, while the latter is highly sticky recurring monetization of installed base. As cumulative shipments increase and the proportion of high-end pumps (after full process coverage) rises, there is room for structural gross margin improvement, but in the short term, it is suppressed by foreign competitors' price cuts.
Accounting Red Flags:
| Issue | Severity | Evidence |
|---|---|---|
| Fair value change gains/losses account for an extremely high proportion of profit | High | FY2025 fair value change gains of 752 million, accounting for 78.4% of total profit. Core operating profit is almost entirely obscured by financial asset volatility. |
| Inventory write-down ratio far exceeds peers | Medium | Provision ratio of 10.44% (peer average ~2%), with spare pump write-downs accounting for 43.08% of total inventory write-downs. The Beijing Stock Exchange previously questioned the commercial substance of this. |
| Increasing reliance on government subsidies | Medium | Government subsidies increased from 55 million in FY2023 to 130 million in FY2025, with the ratio to non-recurring net profit rising from 75% to 126%. |
Intertemporal Consistency:
| Indicator | Multi-period Trend | Consistent with Management Explanation? |
|---|---|---|
| Gross Margin | FY2023 33.02% → FY2024 29.44% → FY2025 26.78% (from IPO prospectus), declining for three consecutive years | Consistent – management explains as competitive price pressure + product mix change |
| Photovoltaic Revenue Share | FY2023 29.24% → FY2025 6.36%, structural contraction | Consistent – PV overcapacity, company proactively adjusted customer mix |
| OCF / Non-recurring Net Profit | FY2023 0.65x → FY2024 2.02x → FY2025 1.86x, high volatility | Not explained by company – FY2023 low figure may be related to slow receivables collection from PV customers |
| Indicator | Value | Notes |
|---|---|---|
| Stock Price | 75.51 yuan | Close on 2026-07-24 |
| Total Shares | 223.8391 million shares | Post-IPO |
| Market Cap | 16.902 billion yuan | |
| PE (TTM) | 16.92x | 2nd percentile over last 5 years (parent incl. FV gains, not meaningful) |
| Non-recurring PE (FY2025) | 164.1x | Only 3 months since listing, percentile not meaningful |
| PB | 6.39x | 29th percentile over last 5 years (depressed by trading financial assets) |
| Net Cash | 2.115 billion yuan | 9.45 yuan per share (cash-like assets 2.342 billion − interest-bearing debt 227 million) |
| Core Business EV | 14.787 billion yuan | Market cap − net cash |
| Company | PE (TTM) | PB | Revenue Growth | ROE | Notes |
|---|---|---|---|---|---|
| Zhongke Instrument (920186) | 16.9x | 6.4x | +19.3% | 40.9% | PE distorted by FV gains |
| Edwards / Atlas Copco | ~35x | ~7x | +5–8% | ~18–22% | Global vacuum pump leader |
| Ebara (6361.T) | ~18x | ~2.5x | +10% | 15.6% | Diversified industrial, precision machinery includes dry pumps |
| Pfeiffer Vacuum | ~25x | ~3x | −3.9% | ~8–12% | Mainly turbomolecular pumps |
| Hanbell Precise Machinery (002158) | ~6x | ~1.7x | −20% | 11.0% | Dragged by PV vacuum pump downturn |
| NAURA Technology Group (002371) | ~70–112x | ~10–16x | +30% | ~8–12% | Domestic semiconductor equipment platform leader |
Current price 75.51 yuan → market cap 16.9 billion → core business EV = 14.787 billion (excluding net cash of 2.115 billion).
Assuming a 35–45x PE exit (benchmark: Atlas Copco vacuum ~25x + domestic substitution growth premium), implied 2028E non-recurring net profit needs to reach 330–420 million. For reference: consensus sell-side 2028E parent net profit ~322 million (non-recurring lower); company FY2025 non-recurring only 103 million – requiring a 3-year CAGR of 47–60%, far exceeding historical growth (FY2023–FY2025 non-recurring CAGR ~19%) and sell-side expectations (~34%).
Two-way test of demand inflection: The implied growth rate at current price (47–60% non-recurring CAGR) is at the upper end of precedents set by NAURA (non-recurring CAGR ~35%) and AMEC (~28%). The company's small base (100 million non-recurring) makes high growth mathematically easier, but a gross margin of only 26.78% (far below peers' 30%+) and pre-production depreciation/R&D could suppress non-recurring margins. The inflection direction is correct, but the current price already prices in a success scenario, leaving very narrow room for error.
| Layer | Per Share Value | Explanation |
|---|---|---|
| Asset Value (Floor) | 14.4 yuan | Net assets per share (including financial assets like Piotech) |
| EPV Zero Growth | 14.6 yuan | WACC 9%, based on current recurring non-recurring 0.46 yuan/share + net cash 9.45 yuan/share |
| Growth Option | 60.9 yuan | Current price 75.51 − EPV 14.56, accounting for ~81% of current price |
The current price is primarily supported by the growth option (growth option ~81% of current price, estimated by EPV model). For a confirmed structural growth inflection, EPV zero growth serves as a downside floor rather than a value judgment – actual value depends on the ramp-up scenario.
| Scenario | Probability | Fair Value Range | Key Determinant |
|---|---|---|---|
| Bear | 30% | 20–25 yuan | Advanced node qualification delayed/failed, memory expansion disproven, gross margin drops below 22%. 2028E non-recurring ~150 million, exit PE 20–25x. Reference: most conservative sell-side forecast (Kaiyuan Securities 2028E parent 314 million). Applying a low-cycle exit PE of 20x gives ~37.5 yuan/share – the bear case 20–25 yuan range is more conservative and represents a stress test scenario. |
| Base | 50% | 48–60 yuan | Expansion on track, 2028E market share 12.7% → 18–20%, non-recurring net profit 250–280 million. Exit PE 35–40x (benchmark: Atlas Copco vacuum 25x + domestic substitution growth premium 10–15x). Ramp-up estimate: 2026–2028E revenue CAGR ~30% (1.6→2.2→2.9 billion), non-recurring CAGR ~34% (130→200→250 million). Exit year non-recurring 250 million × 35x + net cash → ~54 yuan/share (midpoint). |
| Bull | 20% | 72–90 yuan | AI demand exceeds expectations (HBM ramp-up) + overseas (TSMC/SK Hynix) volume orders + full process qualification completed ahead of schedule. Non-recurring net profit 2028E 400 million+. Exit PE 40–45x (benchmark: NAURA current PE ~70x, apply BSE discount to Zhongke Instrument). Ramp-up estimate: 2026–2028E revenue CAGR ~40%, non-recurring CAGR ~56%. Exit year non-recurring 400 million × 40x + net cash → ~81 yuan/share (midpoint). |
Internal Earnings Forecast:
| Year | Revenue | Non-recurring Parent Net Profit | Key Assumptions | Management Guidance |
|---|---|---|---|---|
| FY2026E | 1.60–1.70 billion | 120–150 million | Dry pump unit sales 12,000–13,000, ASP ~85,000 yuan | Sufficient order backlog, good capacity utilization |
| FY2027E | 2.20–2.35 billion | 180–220 million | Capacity ramps to ~17,000–18,000 units, ASP ~88,000 yuan | After IPO projects reach full capacity, annual increase of 17,000 units |
Sell-side consensus: 2026E revenue ~1.60 billion, clean parent net profit ~229 million; 2027E revenue ~2.29 billion, parent net profit ~268 million. Our forecasts are broadly in line with consensus.
Valuation Judgment: Overvalued. Current price of 75.51 yuan represents a 26% premium to the base case fair value ceiling of 60 yuan, and a 51% premium to the probability-weighted value of ~50 yuan. Even the bull scenario (2028E non-recurring 400 million, 40x PE + net cash) has a fair value ceiling of only 90 yuan – the current price is only 19% below the bull case ceiling, while the downside to the base case floor is 36%. Risk/reward is unfavorable. Quality is excellent but price does not match – wait for a pullback to 50–55 yuan (base case midpoint) before reassessing.
The global semiconductor dry vacuum pump market in 2024 was approximately 12.574 billion yuan (approx. US$1.75 billion), with mainland China at about 5.211 billion yuan (from Zhongke Instrument's IPO prospectus, citing SEMI data). The domestic photovoltaic dry vacuum pump market is about 4.7–5.7 billion yuan (CPIA / iVacuum estimate). Overall, the combined domestic IC + PV dry pump market accessible to Zhongke Instrument is around 10–11 billion yuan.
Growth outlook: QY Research estimates the global semiconductor dry pump market CAGR at ~8.8% for 2026–2032. Shenwan Hongyuan estimates China's semiconductor vacuum pump market at 6.34 / 7.43 billion yuan for 2026/2027. Domestic growth (10–12%) outpaces global growth, driven by accelerated wafer fab expansion and domestic substitution.
Quantified Demand Inflection Chain (1.8 structural inflection):
Upstream: Basic raw materials (aluminum alloy / stainless steel / titanium alloy) + precision components (screw rotors / scroll discs / bearings) + electrical components (inverters / servo motors). Suppliers are fragmented; top 5 suppliers account for 28–35%. Zhongke Instrument has moderate bargaining power over upstream.
Midstream: Dry vacuum pump R&D design, precision machining, assembly integration, and testing/validation – this segment has the highest technical barriers and highest value concentration (gross margin 25–38%). Zhongke Instrument operates in this segment and is the only domestic company to achieve mass application in all processes at the 14nm advanced node.
Downstream: IC wafer fabs (YMTC / CXMT / SMIC / TSMC / SK Hynix) + semiconductor equipment OEMs (NAURA / Piotech) + photovoltaic cell manufacturers (LONGi, etc.) + large-scale scientific facilities. Downstream customers are concentrated (top 5 account for 44%), but qualification barriers are extremely high (2–5 years), switching costs are substantial, and stickiness is strong.
Value Distribution: Gross profit primarily remains in the midstream manufacturing and upstream precision component segments. Zhongke Instrument has moderately strong bargaining power over downstream (due to qualification barriers), but its scale is smaller than international giants.
Demand: Volume – AI drives global wafer fab CAPEX upward (2025 global equipment sales US$135.1 billion, +15%), mainland China remains at historically high levels (US$49.3 billion); Price – advanced node pump unit prices are upgrading from 80,000–100,000 yuan to 120,000–150,000 yuan.
Supply: Global IC dry pump market dominated by Edwards (22–26%), Ebara (15–18%), and Kashiyama (12–15%); CR5 is ~78%. Domestic localization rate ~27–30%, with Zhongke Instrument holding the top domestic share (~45%+). Zhongke Instrument's 2025 capacity 10,600 units; post-IPO projects target 26,500 units.
Barriers to Entry: Extremely high – threefold: ① Technology qualification (2–5 year validation cycle); ② R&D platform (three national centers / 103 invention patents); ③ Product coverage (must be compatible with 30+ equipment vendors and hundreds of machine types). Only Zhongke Instrument has crossed the 14nm / 128-layer NAND threshold domestically.
Competitive Intensity: International leaders have technological advantages but slower service response and higher prices (+30–50%); domestic low-to-mid end faces price competition (Hanbell / Tongjia Hongrui), but in the IC advanced node area, Zhongke Instrument is the sole domestic volume supplier.
Strongly positive – US export controls (BIS entity list expansion) directly accelerate domestic wafer fabs' localization of components; Big Fund Phase I/II provide financial and technical support (Big Fund holds 15.14% of Zhongke Instrument); "02 Special Project" and other national-level R&D programs provide continuous support (Zhongke Instrument has undertaken the "02 Special Project" four times).
Zhongke Instrument is the largest domestic company by IC dry vacuum pump shipments in China (2024 IC market share 12.72%, first domestically) and the only domestic supplier achieving mass application in 14nm advanced nodes and all process steps. Moat sources: ① Technology qualification barriers (2–5 year validation); ② National-level R&D platforms + major project endorsements; ③ Full process coverage + breadth of compatibility with 30+ equipment vendors. Share trend is clearly upward (targeting 18–22% by 2027). Core risks are foreign competitors' price cuts and sustained gross margin pressure.
The semiconductor equipment components industry has the following defining dimensions:
Cumulative Shipments and Installed Base Monetization: As of the IPO prospectus date, Zhongke Instrument has cumulatively shipped over 40,000 dry vacuum pumps (over 30,000 in IC). Repair and maintenance services (FY2025 share 10.61%, +74.45% YoY) accelerate with growing installed base – this is the core monetization logic of the "razor + blades" model. If 50% of the 40,000 units are under service contracts, with an average annual maintenance fee of ~15,000 yuan per unit, the annual maintenance revenue opportunity is about 300 million yuan, roughly double the current ~137 million yuan.
Process Node Coverage and Price Gradient: Mature node clean process pumps average ~70,000–80,000 yuan/unit; advanced node harsh process pumps average ~120,000–150,000 yuan/unit. The company's current product mix is primarily mature node; after full process validation, the increased share of high-end pumps will drive both ASP and gross margin higher.
Order Backlog and Contract Liabilities: As of end-Q1 2026, contract liabilities were 232 million yuan (+82.5% YoY), reflecting a healthy order backlog. Relative to FY2025 revenue of 1.291 billion, contract liabilities represent ~18% of annual revenue, indicating strong revenue visibility over the next 2–3 quarters.
Overall Stance: Neutral, Confidence 0.58.
Zhongke Instrument is one of the highest-quality names in the domestic semiconductor equipment components sector – absolute leader in domestic dry vacuum pumps, sole entrant into advanced nodes, and a clear structural demand inflection point. However, the current share price of 75.51 yuan fully – or even excessively – prices in the growth expectations for the next three years. The probability-weighted fair value across three scenarios is approximately 50 yuan, implying a margin of safety of −36%. Risk/reward is unfavorable: even in the bull case, upside is only ~19%; downside to the base case is 36%.
Strategy Recommendation: Do not chase at current levels. Reassess only when one of the following conditions is triggered:
Core Risk Warnings:
Key Catalysts Calendar for the Next 12 Months:
This report is based on public information and does not constitute investment advice. Report date: 2026-07-24.